- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
- Programs are part of Allergan's robust gastroenterology pipeline, which also includes studies in diabetic gastroparesis and nonalcoholic steatohepatitis
PR Newswire
DUBLIN, Oct. 5, 2018